# RNN 2nd Gen Model Regeneron Pharmaceuticals, Inc. Pharmaceutical preparations

Stock predictor AI models:
69.57% successful of 92 deals
$ 463.05 Last close price
at 01-mar-2021

REGN

Model's trade recommendations 3.33% Return for period

19.32% Annual return

$31.89B Market Cap

β 1.44  

REGN

Model (following trade recommendations)

REGN

Underlying stock

S&P 500

Index
Return for period 3.33%
-8.86%
1.78%
52wk return 34.31%
-0.37%
16.82%
52wk Range
429.78—658.21
2000.54—2399.63
Sortino ratio 2.16
Sharpe ratio 1.38
Norm. RMSE 0.46%
Downside risk 8.42%
Volatility 0.00%
  • BUY Analysts consensus recommendation

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Regeneron Pharmaceuticals, Inc. (REGN) stock is a 2nd Generation Non-linear Autoregressive (NAR) model based on the LSTM/GRU Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for REGN model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for REGN.

Model is being retrained on a regular basis.

Float 94M
P/E 21.43
Shares Outstanding 108M
% Held by Insiders 12.42%
% Held by Institutions 66.37%
EPS (last reported FY) $13.41
EPS (last reported Q) $4.46
EPS, estimated (last reported Q) $4.18
Total revenues $6 B
Net income $1 B